Evidence map›Paper›PMID 39702242›Full record

ArticleGenome medicine2024

HGVS Nomenclature 2024: improvements to community engagement, usability, and computability.

Reece K Hart, Ivo F A C Fokkema, Marina DiStefano, Ros Hastings, Jeroen F J Laros, Rachel Taylor, Alex H Wagner, Johan T den Dunnen

Abstract read
In one paragraph

Article in Genome medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Genetic landscape of phenylketonuria in Brazil.Orphanet journal of rare diseases · 2026
    Article
  9. Article
  10. A UniqueInternational journal of molecular sciences · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Database ofKidney international reports · 2026
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Reece K HartMyOme, Inc., San Francisco, USA. reecehart@gmail.com.ORCID 0000-0003-3463-0775
Ivo F A C FokkemaDepartment of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-1368-1939
Marina DiStefanoMedical and Population Genetics Group, The Broad Institute of MIT and Harvard, Cambridge, USA.ORCID 0000-0002-8218-5111
Ros HastingsGenQA, Oxford University Hospitals NHS Trust, Oxford, UK.ORCID 0009-0001-5860-5577
Jeroen F J LarosDepartment of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-8715-7371
Rachel TaylorEMQN CIC, Manchester, UK.ORCID 0000-0002-1235-4303
Alex H WagnerInstitute for Genomic Medicine, Nationwide Children's Hospital, Columbus, USA.ORCID 0000-0002-2502-8961
Johan T den DunnenDepartment of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-6304-1710

Funding

Development and validation of a computable knowledge framework for genomic medicineR35HG011949 · NHGRI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI WAGNER, ALEX HANDLER · 2021 to 2025
$2.4M
NHGRI NIH HHS R35 HG011949
6 · The paper itself

Abstract

backgroundThe Human Genome Variation Society (HGVS) Nomenclature is the global standard for describing and communicating variants in DNA, RNA, and protein sequences in clinical and research genomics. This manuscript details recent updates to the HGVS Nomenclature, highlighting improvements in governance, community engagement, website functionality, and underlying implementation of the standard.

methodsThe HGVS Variant Nomenclature Committee (HVNC) now operates under the Human Genome Organization (HUGO), facilitating broader community feedback and collaboration with related standards organizations. The website has been redesigned using modern documentation tools and practices. The specification was updated to include guidance for transcript selection and to align with recent cross-consortia recommendations for the representation of gene fusions. A formal computational grammar was introduced to improve the precision and consistency of variant descriptions.

resultsMajor improvements in HGVS Nomenclature v. 21.1 include a redesigned website with enhanced navigation, search functionality, and mobile responsiveness; a new versioning policy aligned with software management practices; formal mechanisms for community feedback and change proposals; and adoption of Extended Backus-Naur Form (EBNF) for defining syntax. The specification now recommends MANE Select transcripts where appropriate and includes updated guidance for representing adjoined transcripts and gene fusions. All content is freely available under permissive licenses at hgvs-nomenclature.org.

conclusionsThese advancements establish a more sustainable foundation for maintaining and evolving the HGVS Nomenclature while improving its accessibility and utility. The introduction of formal computational grammar marks a crucial step toward unambiguous variant descriptions that can be reliably processed by both humans and machines. Combined with enhanced community engagement mechanisms and improved guidance, these changes position the HGVS Nomenclature to better serve the evolving needs of clinical and research genomics while maintaining the stability that users require.

Indexed as

Terminology as TopicCommunity ParticipationGenetic VariationGenome, HumanGenomicsGuidelines as TopicHumansSoftwareBioinformaticsClinical genomicsHGVSSequence variationStandards

Identifiers

PMID39702242
PMCPMC11660784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.